A healthcare provider shares her journey with multiple myeloma, discussing the physical, emotional and financial challenges ...
Each monthly installment examines an aspect of multiple myeloma care, including delivering the diagnosis, building trust, ...
Results from the MagnetisMM-5 study showed that Elrexfio significantly improved progression-free survival, which means ...
Although patients with the same cancer diagnosis may respond very differently to treatment, clinicians still have limited ...
Once a disease with poor outcomes, multiple myeloma now has new promise thanks to CAR T-cell therapy, which reprograms a patient’s immune cells to attack cancer. Some patients are experiencing ...
Multiple myeloma is a cancer of the bone marrow. And treatment is not a walk in the park.
Topline data from the MagnetisMM-5 study demonstrate the superiority of elranatamab monotherapy over daratumumab plus pomalidomide and dexamethasone in double-class exposed multiple myeloma patients.
Bispecific antibodies are currently approved as late-line therapy, but they are moving up to earlier lines “as they prove ...
SurvivorNet on MSN
CAR T-cell therapy and the hope for a cure in multiple myeloma
CAR T-cell therapy is a treatment that uses a patient’s own T cells, genetically reprograms them in a lab to recognize ...
Although patients with the same cancer diagnosis may respond very differently to treatment, clinicians still have limited ...
A new research paper was published in Volume 17 of Oncotarget on April 28, 2026, titled "Targeted therapeutics and U.S. population-level mortality trends in multiple myeloma: A SEER-based analysis ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results